Literature DB >> 21733718

Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines.

Yongjing Chen1, Qin Wang, Bimin Shi, Ping Xu, Zhenhua Hu, Lixiong Bai, Xueguang Zhang.   

Abstract

PD-L1 (CD274) is a critical membrane-bound costimulatory molecule that inhibits immune responses through its receptor, PD-1. Previous data have showed that this molecule is associated with autoimmune diseases, chronic viral infections and tumor immune escape. However, the existence and role of soluble form of human PD-L1 (sPD-L1) remain unknown. We show here that a novel enzyme-linked immunosorbent assay (ELISA) was developed to detect the sPD-L1 protein. Many culture supernatants of the PD-L1+ cell lines contain high levels of this factor. Interestingly, the sPD-L1 is detectable in human serum and the concentration increases in an age-dependent manner. Human sPD-L1 has a unique protein form in the serum and the matrix metalloproteinase inhibitor (MMPI) could suppress sPD-L1 production. Moreover, the sPD-L1 could specially bind to PD-1. Together, these data demonstrate that the existence of circulating sPD-L1 in human serum might play an important role in immunoregulation.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733718     DOI: 10.1016/j.cyto.2011.06.004

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  80 in total

1.  PD-L1 mediated the differentiation of tumor-infiltrating CD19+ B lymphocytes and T cells in Invasive breast cancer.

Authors:  Honggeng Guan; Yang Lan; Yuqiu Wan; Qin Wang; Cheng Wang; Longjiang Xu; Yongjing Chen; Wenting Liu; Xueguang Zhang; Yecheng Li; Yongping Gu; Zemin Wang; Fang Xie
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

2.  Identification and characterization of an alternative cancer-derived PD-L1 splice variant.

Authors:  Nadia B Hassounah; Venkat S Malladi; Yi Huang; Samuel S Freeman; Ellen M Beauchamp; Shohei Koyama; Nicholas Souders; Sunil Martin; Glenn Dranoff; Kwok-Kin Wong; Chandra S Pedamallu; Peter S Hammerman; Esra A Akbay
Journal:  Cancer Immunol Immunother       Date:  2018-12-18       Impact factor: 6.968

3.  Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells.

Authors:  Fatma Aboulnasr; Ashton Krogman; Rondell P Graham; Nathan W Cummins; Anisha Misra; Enrique Garcia-Rivera; Jeff R Anderson; Sekar Natesampillai; Nicole Kogan; Murali Aravamudan; Zilin Nie; Thomas D Y Chung; Richard Buick; Andrew L Feldman; Rebecca L King; Anne J Novak; Stephen M Ansell; Saad Kenderian; Andrew D Badley
Journal:  Clin Cancer Res       Date:  2020-07-15       Impact factor: 12.531

Review 4.  Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.

Authors:  Yi Xia; L Jeffrey Medeiros; Ken H Young
Journal:  Biochim Biophys Acta       Date:  2015-10-16

5.  Label-free and specific detection of soluble programmed death ligand-1 using a localized surface plasmon resonance biosensor based on excessively tilted fiber gratings.

Authors:  Binbin Luo; Yajie Wang; Huafeng Lu; Shengxi Wu; Youming Lu; Shenghui Shi; Lingchen Li; Shanghai Jiang; Mingfu Zhao
Journal:  Biomed Opt Express       Date:  2019-09-13       Impact factor: 3.732

6.  Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1.

Authors:  Sarah A Ingersoll; Julie Laval; Osric A Forrest; Marcela Preininger; Milton R Brown; Dalia Arafat; Greg Gibson; Vin Tangpricha; Rabindra Tirouvanziam
Journal:  J Immunol       Date:  2015-04-29       Impact factor: 5.422

7.  Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay.

Authors:  Yan G Ni; Xiling Yuan; John A Newitt; Jon E Peterson; Carol R Gleason; Jonathan Haulenbeek; Rasa Santockyte; Virginie Lafont; Frank Marsilio; Robert J Neely; Binodh DeSilva; Steven P Piccoli
Journal:  AAPS J       Date:  2015-05-01       Impact factor: 4.009

8.  Increased soluble and membrane-bound PD-L1 contributes to immune regulation and disease progression in patients with tuberculous pleural effusion.

Authors:  Xue Pan; Anyuan Zhong; Yufei Xing; Minhua Shi; Bin Qian; Tong Zhou; Yongjing Chen; Xueguang Zhang
Journal:  Exp Ther Med       Date:  2016-08-23       Impact factor: 2.447

Review 9.  Soluble immune checkpoints in cancer: production, function and biological significance.

Authors:  Daqian Gu; Xiang Ao; Yu Yang; Zhuo Chen; Xiang Xu
Journal:  J Immunother Cancer       Date:  2018-11-27       Impact factor: 13.751

10.  Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.

Authors:  Roberta Carosio; Vincenzo Fontana; Luca Mastracci; Paola Ferro; Federica Grillo; Barbara Banelli; Pier Aldo Canessa; Paolo Dessanti; Antonella Vigani; Anna Morabito; Ulrich Pfeffer; Alessandro Poggi; Silvio Roncella; Maria Pia Pistillo
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-20       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.